Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ChinaWhys was a Shanghai-based risk management and corporate investigation consultancy founded in 2003 by Peter Humphrey and Yu Yingzeng. The firm specialized in due diligence, fraud investigation, and compliance services for multinational corporations operating in China, frequently serving the pharmaceutical and healthcare industries. It gained international prominence during the 2013 GlaxoSmithKline (GSK) bribery scandal, having been hired by GSK to investigate a whistleblower. The firm's operations effectively ended following the arrest and subsequent conviction of its founders by Chinese authorities for illegally obtaining private information. Its history remains a significant case study in the complexities of corporate compliance and investigative work within the Chinese regulatory environment.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chinawhys.